银屑病患者血小板-淋巴细胞复合物高水平与抗TNF-α治疗更好应答相关
该研究比较银屑病患者与健康供者的血小板-淋巴细胞复合物(PLyC)水平,并分析血小板结合对辅助性T细胞分泌IL-17A的影响,以及抗TNF-α治疗对应答者与非应答者PLyC的作用。结果显示银屑病患者PLyC升高,抗TNF-α治疗使PLyC正常化,且应答者基线血小板-辅助性T淋巴细胞复合物百分比显著更高,提示PLyC可能是抗TNF-α治疗应答的预后生物标志物。
要点
- 银屑病患者PLyC水平较健康供者升高。
- 抗TNF-α治疗使银屑病患者PLyC值正常化,主要见于应答者。
- 应答者基线血小板-辅助性T淋巴细胞复合物百分比显著更高。
核心结论
- PLyC在银屑病患者中升高,抗TNF-α治疗后复合物数量下降,尤其在应答者组。
- PLyC可能是抗TNF-α治疗应答的预后生物标志物,但需前瞻性研究验证。
研究设计与样本
- 研究比较银屑病患者与健康供者的PLyC水平。
- 研究分析血小板结合对辅助性T细胞分泌IL-17A的影响。
- 研究评估抗TNF-α治疗对应答者与非应答者银屑病患者PLyC的影响。
主要发现
- 银屑病患者PLyC增加。
- 血小板-淋巴细胞复合物群体中IL-17分泌细胞百分比更高,且这些细胞倾向于分泌更多IL-17A。
- 抗TNF-α治疗的银屑病患者PLyC值正常化。
- 应答者组基线血小板-辅助性T淋巴细胞复合物百分比显著更高。
临床怎么用
- 基线PLyC水平可能有助于预判银屑病患者对抗TNF-α治疗的应答。
- 抗TNF-α治疗过程中PLyC下降可能反映治疗应答。
局限性
- PLyC作为抗TNF-α治疗应答预后标志物的结论需前瞻性研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Psoriasis is currently considered to be an immune-mediated disease whose patho-mechanisms involve platelet activation, which seems to correlate with the activity of the disease. Platelet activation is associated with the formation of platelet-lymphocyte complexes (PLyC), although their significance remains unknown. Moreover, biological treatments that target tumor necrosis factor-α (TNF-α) reduce platelet activation. To clarify the significance of PLyC, we compared their levels in patients with psoriasis with those of healthy donors and determined whether platelet binding modifies the secretion of IL-17A by T helper cells. Finally, we assessed the effect of anti-TNF-α treatment on PLyC in responder and non-responder patients with psoriasis. Ours results demonstrated an increase in PLyC in patients with psoriasis. Moreover, the percentage of IL-17-secreting cells was observed to be higher in the platelet-lymphocyte complex population, and these cells tended to secrete greater amounts of IL-17A. Psoriasis patients treated with anti-TNF-α normalized platelet-lymphocyte complex values, and the basal percentage of platelet-T helper lymphocyte complexes was significantly higher in the responder group. In conclusion, PLyC are increased in psoriasis patients, and the number of complexes decreases in response to anti-TNF-α treatment, specifically in the responder group of patients. This finding suggests that PLyC are a prognostic biomarker of response to anti-TNF-α therapy, but prospective studies are necessary to verify these results in patients with psoriasis.
引用
- Sanz-Martínez MT, Moga E, Sánchez Martínez MA, et al. High Levels of Platelet-Lymphocyte Complexes in Patients with Psoriasis Are Associated with a Better Response to Anti-TNF-α Therapy. J Invest Dermatol. 2019. PMID: 31778714. doi:10.1016/j.jid.2019.08.457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。